Boundless Bio, Inc. (BOLD)
NASDAQ · Manufacturing · Pharmaceutical preparations
BOLD price, last 12 months
Key stats
- Previous close
- $2.60
- Open
- $2.61
- Day range
- $2.59 – $2.67
- 52-week range
- $0.9612 – $3.16
- Volume
- 255.4K
- Avg volume (20 days)
- 127.1K
- Market cap
- $60.5M
Performance
Technicals and fundamentals
About Boundless Bio, Inc.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $60.5M